Benchmark Upgrades NeoGenomics to Buy, Announces $11 Price Target
Benzinga Newsdesk 6 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Benchmark analyst Bruce Jackson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and announces $11 price target.
Benchmark analyst Bruce Jackson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and announces $11 price target.